263 results about "Cellular secretion" patented technology

Human/human hybrid cells were made via fusion of human embryonic kidney cells (293S) and modified Burkitt's lymphoma cells (2B8). The fusion cells are useful as host cells for the recombinant expression of mammalian genes. The advantages of using these hybrid clones of human kidney- and B-cells, called HKBs, for mammalian gene expression, include (i) the cells are negative for immunoglobulin expression, (ii) the cells grow easily in plasma protein-free medium (with or without the addition of recombinant insulin) as suspension cultures in a shake flask or in a fermenter (iii) the cells are very susceptible for transfection of DNA, and (iv) the cells secrete high levels of heterologous recombinant proteins, such as recombinant monoclonal antibodies, soluble ICAM-1, rIL-4, and rFVIII.

Methods and devices are provided herein for identifying a cell population comprising an effector cell that exerts an extracellular effect. In one embodiment the method comprises retaining in a microreactor a cell population comprising one or more effector cells, wherein the contents of the microreactor further comprise a readout particle population comprising one or more readout particles, incubating the cell population and the readout particle population within the microreactor, assaying the cell population for the presence of the extracellular effect, wherein the readout particle population or subpopulation thereof provides a direct or indirect readout of the extracellular effect, and determining, based on the results of the assaying step, whether one or more effector cells within the cell population exerts the extracellular effect on the readout particle. If an extracellular effect is measured, the cell population is recovered for further analysis to determine the cell or cells responsible for the effect.

A versatile compartmentalized cell culture device, with a selectively permeable membrane separating the compartments, provides many attributes relative to traditional devices. It can be configured for high-density cell culture, co-culture, and sample dialysis while rolling or standing still. It can also be configured for continuous movement of liquid between compartments. The wide combination of attributes not found in other membrane based cell culture and bioprocessing devices includes more cell capacity, more cell secreted product capacity, higher cell and product density, increased medium capacity, minimized use of exogenous growth factors, compatibility with standard cell culture equipment and protocols, increased scale up efficiency, capacity to function when rolling or standing still, capacity for perfusion without the need for pumps, and more efficient sample dialysis.

The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (Z) linked to a terminal group (W), characterized in that the linkage between the arm (Z) of the ligand (W-Z) and the component (M) prevents intracellular entry of the compound (W-Z-M) and/or inhibits expression of the marker (M), in that said linkage can be selectively cleaved by factors secreted by target cells so as to permit expression of the marker (M) or entry of the therapeutic agent (M) into said target cells, and in that the terminal group (W) provides for the stability of the compound (W-Z-M) in the serum and circulating blood.

An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.

An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.

Systems, methods, compositions, and kits for measuring secreted factors from cells are disclosed herein, including those capable of determining single cell secretion activity and protein expression and/or gene expression simultaneously. Disclosed herein include bispecific probes comprising an anchor probe capable of specifically binding to a surface cellular target of a cell, and a capture probe capable of specifically binding to a secreted factor secreted by a cell that is associated with the capture probe. Also disclosed herein include secreted factor-binding reagents capable of specifically binding to a secreted factor bound by a capture probe, where a secreted factor-binding reagent can comprise a secreted factor-binding reagent specific oligonucleotide comprising a unique factor identifier sequence for the secreted factor-binding reagent.

The invention discloses a preparation method of exosome capable of simultaneously loading a chemical drug and a nano-material. The preparation method comprises the following steps: 1) extracting cellsecreted exosome from cell culture supernatant by utilizing a classic differential ultra-speed centrifuging method; 2) simultaneously loading curcumin and nano ferroferric oxide in a water solution into the exosome by utilizing an electroporation method; 3) measuring OD260nm (an RNA (Ribonucleic Acid) characteristic absorption peak) to identify whether perforation is successful or not; 4) after finishing the perforation, immediately putting a mixed solution into a cell culture box and hatching for 1h, so as to facilitate exosome membrane repairing; 5) carrying out 100000g ultra-speed centrifuging to remove free curcumin and nano ferroferric oxide, so as to obtain the compound exosome capable of simultaneously loading the curcumin and the nano ferroferric oxide. The method disclosed by themethod is simple and feasible and high in success rate; in the prepared compound exosome, the loading amounts of the curcumin and the nano ferroferric oxide can meet in vivo and in vitro treatment andimaging requirements and a novel tool is provided for targeting diagnosis and treatment of various chronic diseases including tumors.

The present invention provides compositions and methods for the secretion and the translocation of a compound of interest by a bacterial minicell. In certain embodiments, the invention provides a bacterial minicell comprising at least one component of the type III secretion system (T3SS), which provides a safe and efficient system for secretion and translocation. In one embodiment, the invention allows for the delivery of an antigen to a cell or subject in order to induce an immune response.

The invention relates to compositions comprising (i) adipose tissue-derived cell secretions or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of adipose tissue-derived cell secretions and an adipose tissue-derived cell suspension, optionally comprising adipocytes, and to their use in pharmaceutical compositions and methods for treatment of various conditions. The invention also relates to improved methods, agents and compositions for cryopreservation of cells.

The invention discloses monoclonal antibody of anti-dengue virus E protein, which is generated through the secretion of the mice hybridoma cells 2B10 with the collection number of CGMCC No.2407; the monoclonal antibody provided by the invention has the advantages that the comprehensive effectiveness is high, the monoclonal antibody can be specifically combined with the dengue virus and can be applied to the preparation of the novel and effective medicine which can prevent and cure dengue virus infection and can also be manufactured into reagent kits for testing dengue virus.

The invention relates to a skin regeneration compound in the field of cosmetic skin care. The skin regeneration compound comprises a green plum-blossom extractive and a pollen pini extractive, wherein the weight percentage of the green plum-blossom extractive is 0.05-0.5%, the green plum-blossom extractive can scavenge the free radical, the balance of the free radical is good for maintaining the activity of the cell so that the cell can secrete more extracellular matrixes and collagens to effectively maintain the integrity of the skin structure, enhance the elasticity of the skin and strengthen the skin anti-aging function. The weight percentage of the pollen pini extractive is 0.5-2.0%, the active ingredients of the pollen pini extractive can strengthen the absorption for the active component in the pollen pini extractive and the bad skin absorbency problem due to a single antioxidant substance such as the green plum-blossom extractive can be effectively improved; additionally, the skin moisturizing ability is strengthened, the skin elasticity is improved and the anti-aging function is reached.

The invention discloses a method and application for promoting cells to secrete exosomes, and relates to the fields of biological materials, tissue engineering and regenerative medicines. According tothe method, the cells are stimulated by active signals of a biological material, and the exosomes generated by the cells are collected, and are used for tissue wound treatment. The operation route ofthe method and the application scheme of the obtained exosomes are described in detail, under the stimulation effects of bioactive glass chemical signals, electrostatic spinning fiber membrane structure signals and chemical/structural combination signals, more exosome particles can be secreted by mesenchymal stem cells and umbilical vein endothelial cells, and the exosomes can promote the corresponding target cells to express higher levels of functional genes, secrete more multifunctional proteins and carry out deep functional differentiation, so that the tissue wound surface can be rapidly repaired. The exosomes obtained by the method disclosed by the invention have the characteristics of higher yield and stronger tissue repair promotion function.

The invention relates to a pre-stimulating stem cell as well as a preparation method and application thereof. The preparation method comprises the following steps of selecting non-target stem cells asauxiliary cells; inducing the auxiliary cells for pyroptosis; obtaining pyroptosis cells, secreta of pyroptosis cells and/or extracts of the pyroptosis cells for culturing stem cells. The preparationmethod provided by the invention can be used for obtaining the stem cells prestimulated by the secreta of the pyroptosis cells; the stem cells can adapt to the natural inflammatory environment; the restoration capability of the stem cells on the damage region can be improved; the method belongs to new breakthrough in the seed material pretreatment in the tissue engineering field; meanwhile, a feasible scheme is provided for pre-stimulating stem cells and solving the problem of clinic disease treatment.

The present invention relates to compositions and methods for using a minibody. Minibodies described herein comprise a secretion signal, a variable heavy chain fragment, a variable light chain fragment, a constant chain fragment, and a hinge domain between the variable light chain fragment and the constant chain fragment. One aspect includes a nucleic acid encoding a minibody. Other aspects include compositions comprising a minibody and a modified T cell comprising a nucleic acid encoding a minibody. Also included are methods and pharmaceutical compositions comprising the modified T cells for adoptive therapy and treating a condition, such as cancer.

The invention relates to a preparation method of a stem cell secreted factor flexible liposome. The preparation method comprises the steps that 0.100-0.150g of phospholipid, 0.020-0.030g of cholesterol, 0.2-0.3mg of vitamin E are dissolved by using 10ml of organic solvent, decompression and rotary evaporation are performed to remove the organic solvent and form a lipid film, a stem cell secreted factor solution is hydrated with the lipid film to form a stem cell secreted factor flexible liposome solution, the obtained stem cell secreted factor flexible liposome solution is subjected to homogenization treatment, and the stem cell secreted factor flexible liposome is obtained. The preparation method of the stem cell secreted factor flexible liposome effectively improves the retention time ofmesenchymal stem cell secreted factors, facilitates the adhesion and absorption of drugs and the skin, reduces stimulation and adverse effects, enhances the penetration ability to reach deep tissue,enhances the curative effects of secreted factors of mesenchymal stem cells, improves the utilization degree of the mesenchymal stem cells, and has no toxic side effects.

The invention provides a new method for regulating intra-cellular and extra-cellular secretion of proteases A under the stress condition. The regulation is realized through over-expressing of an MRL1 gene for coding a vacuolar sorting receptor during knocking-out of an allele of a protease A coding gene, that is, a PEP4 gene. With the adoption of the bred saccharomyces cerevisiae strain, the extra-cellular secretion amount of the proteases A is obviously decreased, the foam retention of draft beer can be improved, the extra-cellular enzyme activity of the proteases A is obviously lower than that of an original strain and is decreased to about 54% of that of the original strain, and meanwhile, compared with the intra-cellular enzyme activity of the original strain, the intra-cellular enzyme activity of the proteases A of the recombinant strain is not changed significantly. A new idea and a new method are provided for reduction of the extra-cellular enzyme activity of the proteases A without change of fermentation characteristics and have the guiding significance in improving the industrial yeast foam stability.

A method of reducing a symptom of a clinical disorder characterized by aberrantly elevated circulating aP2 is carried out by administering to a subject an inhibitor of secreted aP2, secretion of aP2, or a serum aP2 blocking agent. For example, glucose intolerance is reduced following administration of such an inhibitor or agent. Exemplary compositions inhibit cellular secretion of aP2 or bind to circulating aP2, thereby reducing the level or activity of aP2 in blood or serum.

The invention belongs to the technical field of nano materials and oncology, and discloses a composite exosome loaded with tumor apoptosis-promoting protein and anti-cancer small molecules and a preparation method and application of the composite exosome. The composite exosome is EV-T & anti-cancer small molecules, the surface of the composite exosome carries tumor apoptosis-promoting protein TRAIL, and the interior of the composite exosome wraps the anti-cancer small molecules; the method comprises the following steps: transfecting cell resources of human exosome by using a virus vector for expressing a human TRAIL gene to obtain genetically engineered mesenchymal stem cells for stably and highly expressing TRAIL, and marking the genetically engineered mesenchymal stem cells as MSC-flT; then extracting exosomes secreted by the cells from the MSC-flT culture solution to obtain high-purity exosomes carrying TRAIL, and marking the exosomes as EV-T; and wrapping the anti-cancer small molecules into EV-T to obtain the composite exosome. The preparation process is simple, efficient and low in cost; the composite exosome has a remarkable anti-tumor treatment effect, is low in drug dosageand free of toxic and side effects, and provides a nano-drug strategy for clinical treatment of cancers.